| Literature DB >> 35034184 |
Mauro Rigato1, Laura Nollino2, Armindo Tiago3, Luigi Spedicato4, Leopoldo Moises Carlos Simango5, Giovanni Putoto6, Angelo Avogaro7, Gian Paolo Fadini7.
Abstract
AIMS: Diabetes represents a growing public health problem in sub-Saharan Africa, where diabetic retinopathy (DR) is a major cause of permanent visual loss. We reported the results of a remote screening of DR among urbanized Mozambican people with diabetes.Entities:
Keywords: Diabetes; Mozambique; Remote screening; Retinopathy
Mesh:
Year: 2022 PMID: 35034184 PMCID: PMC8761102 DOI: 10.1007/s00592-021-01834-3
Source DB: PubMed Journal: Acta Diabetol ISSN: 0940-5429 Impact factor: 4.087
Characteristics of patients
| Total | NS | S | p value | NDR | DR | p value | |
|---|---|---|---|---|---|---|---|
| N | 536 | 102 | 434 | 307 | 127 | ||
| Age, y | 56 ± 13 | 61 ± 13 | 55 ± 13 | 54 ± 14 | 57 ± 11 | ||
| Male sex, % | 37 | 34 | 38 | 0.5 | 37 | 39 | 0.7 |
| Weight, Kg | 72 ± 14 | 71 ± 15 | 72 ± 14 | 0.4 | 72 ± 14 | 73 ± 12 | 0.4 |
| BMI, Kg/mq | 26 | 25 ± 5.4 | 26 ± 5.3 | 0.5 | 26 ± 5.5 | 26 ± 4.9 | 0.7 |
| Obesity, % | 22 | 23 | 22 | 0.8 | 20 | 27 | 0.2 |
| T2DM, % | 94 | 93 | 95 | 0.6 | 92 | 98 | |
| DM duration, y | 4 (1–9) | 5 (2–11) | 4 (1–9) | 3 (1–7) | 6 (2–12) | ||
HbA1c, % (mmol/mol) | 9.9 ± 3.9 (85 ± 19) | 9.9 ± 3.2 (85 ± 11) | 9.8 ± 4 (84 ± 20) | 0.9 | 9.4 ± 3 (79 ± 9) | 10 ± 5.8 (96 ± 40) | |
| Total-C, mmol/L | 4.8 ± 1.1 | 4.7 ± 1 | 4.8 ± 1.1 | 0.6 | 4.8 ± 1.1 | 4.8 ± 1.2 | 0.6 |
| HDL-C, mmol/L | 1.2 ± 0.6 | 1.3 ± 1 | 1.2 ± 0.3 | 0.3 | 1.2 ± 0.4 | 1.2 ± 0.3 | 0.8 |
| LDL-C, mmol/L | 3.3 ± 1.1 | 3.1 ± 1.3 | 3.3 ± 1 | 0.1 | 3.3 ± 1 | 3.3 ± 1.2 | 0.9 |
| TGL, mmol/L | 1.2 ± 0.8 | 1.2 ± 0.7 | 1.2 ± .8 | 0.8 | 1.2 ± 0.8 | 1.2 ± 0.8 | 0.9 |
| Dyslipidemia, % | 52 | 61 | 50 | 0.1 | 49 | 52 | 0.5 |
| Hypertension, % | 61 | 72 | 58 | 55 | 67 | ||
| Smoke, % | 0.9 | 0 | 1.2 | 0.3 | 1.3 | 0.8 | 0.6 |
| MS, % | 19 | 20 | 20 | 0.8 | 17 | 25 | 0.1 |
| eGFR, ml/min | 90 ± 25 | 83 ± 26 | 91 ± 24 | 93 ± 24 | 87 ± 24 | ||
| CKD, % | 12 | 22 | 10 | 7.8 | 16 | ||
| Neuropathy, % | 50 | 52 | 50 | 0.6 | 51 | 50 | 0.5 |
| CHD, % | 2.8 | 2.9 | 2.8 | 0.9 | 1.3 | 6.3 | |
| Stroke, % | 0.7 | 1 | 0.7 | 0.7 | 0.8 | 0.7 | 0.9 |
| PAD, % | 2.6 | 2.9 | 2.5 | 0.8 | 2.3 | 3.1 | 0.6 |
| Diabetic foot, % | 4.7 | 2.9 | 5.1 | 0.4 | 3.9 | 7.9 | 0.9 |
| Diet only, % | 9.9 | 9.8 | 9.9 | 0.9 | 12 | 3.9 | |
| Metformin, % | 72 | 68 | 73 | 0.3 | 72 | 77 | 0.2 |
| Sulphonilureas, % | 20 | 23 | 19 | 0.4 | 19 | 20 | 0.8 |
| Insulin, % | 27 | 30 | 26 | 0.4 | 21 | 37 |
Significant p-values are bold
NS not suitable for medical reporting; S suitable for medical reporting; NDR non-diabetic retinopathy; DR diabetic retinopathy; BMI body mass index; T2DM type 2 diabetes mellitus; MS metabolic syndrome; eGFR estimated glomerular filtration rate; CKD chronic kidney disease; CHD coronary heart disease; PAD peripheral artery disease
Prevalence of DR and agreement between Italian (ITA) and Mozambican (MZB) readers. DR: diabetic retinopathy; NPRD: non-proliferative diabetic retinopathy; STDR: sight-threatening diabetic retinopathy, including proliferative retinopathy and/or macular oedema. K Cohen < 0.2 indicated poor inter-rater concordance
| ITA | MZB | Person Chi-square | k Cohen | |
|---|---|---|---|---|
| Total DR, % | 29 | 12 | < 0.0001 | 0.18 |
| NPDR, % | 21 | 12 | 0.031 | 0.10 |
| STDR, % | 8.1 | 0.5 | 0.029 | 0.05 |
Univariate and multivariable logistic regression analysis for factors associated with the presence of overall DR. The OR refers to 1-unit increase in independent variables
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | p value | OR | LL | UL | p value | OR | LL | UL |
| T2DM, % | 0.036 | 3.7 | 1.08 | 12 | 0.2 | 2.72 | 0.64 | 11 |
| DM Duration, y | < 0.001 | 1.08 | 1.04 | 1.12 | 1.05 | 1.01 | 1.09 | |
| HbA1c, % | 0.001 | 1.12 | 1.05 | 1.19 | 1.13 | 1.05 | 1.21 | |
| eGFR, ml/min | 0.015 | 0.98 | 0.98 | 0.99 | 0.9 | 0.99 | 0.98 | 1.01 |
| CKD, % | 0.008 | 2.33 | 1.24 | 4.37 | 0.2 | 1.77 | 0.76 | 4.12 |
| Neuropathy, % | 0.5 | 0.85 | 0.56 | 1.29 | Not included | |||
| Hypertension, % | 0.020 | 1.67 | 1.08 | 2.58 | 0.5 | 1.21 | 0.74 | 1.96 |
| CHD, % | 0.009 | 5.10 | 1.50 | 17 | 3.71 | 1.04 | 13 | |
Significant p-values are bold